S&P Futures
5,968.25 +10.00 (+0.17%) Dow Futures
43,971.00 +70.00 (+0.16%) Nasdaq Futures
20,941.50 +47.50 (+0.23%) Russell 2000 Futures
2,413.00 +7.20 (+0.30%) Crude Oil
71.20 -0.49 (-0.68%) Gold
2,667.10 -9.20 (-0.34%)
CRDF Nov 2024 2.500 put
| Previous Close | 0.1500 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.1500 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswireCardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis resulted in a 7.7-fold higher clinical benefit in bev-naïve patients with an ORR of 77% compared to 10% in bev-exposed patients - - Results from this trial, along with translational studies, supported the transition of clinical development of onvansertib to first-line RAS-mutant mCRC - - Initial readout f
Simply Wall St.3 US Penny Stocks With Market Caps Over $40M
As the U.S. stock market attempts to recover from a recent sell-off, major indexes like the Dow Jones and S&P 500 have shown mixed performance, reflecting investor uncertainty amid fluctuating economic indicators. In such a climate, investors often seek opportunities in less conventional areas of the market, including penny stocks. Despite their outdated name, penny stocks represent smaller or newer companies that can offer significant growth potential when backed by strong financials.
